Provided by Tiger Trade Technology Pte. Ltd.

Neurosense Therapeutics Ltd

4.43
-0.3500-7.32%
Post-market: 4.20-0.2300-5.19%18:45 EDT
Volume:40.38K
Turnover:178.12K
Market Cap:8.37M
PE:-0.51
High:4.74
Open:4.71
Low:4.00
Close:4.78
52wk High:26.64
52wk Low:4.00
Shares:1.89M
Float Shares:1.29M
Volume Ratio:1.63
T/O Rate:3.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.7319
EPS(LYR):-8.7319
ROE:-2174.98%
ROA:-247.30%
PB:-5.36
PE(LYR):-0.51

Loading ...

NASDAQ Trade Halt Volatility Trading Pause at 09:46 Am

Reuters
·
Yesterday

NeuroSense CFO Eisenberg Joins ROTH Healthcare Opportunities Conference Investor Meetings

Reuters
·
Sep 29

NeuroSense target adjusted to $52 from $8 at H.C. Wainwright

TIPRANKS
·
Sep 28

Neurosense Therapeutics Ltd : H.c. Wainwright Adjusts Target Price to $52 from $8 to Reflect 1-for-20 Reverse Stock Split

THOMSON REUTERS
·
Sep 28

Press Release: NeuroSense Provides Business Update and Progress for the First Half of 2026

Dow Jones
·
Sep 26

NASDAQ Trade Halt Continues Reason not Available at 06:55 Am

Reuters
·
Sep 14

Neurosense Therapeutics Ltd trading halted, news pending

TIPRANKS
·
Sep 12

NASDAQ Trade Halt Halt News Pending at 07:50 Pm

Reuters
·
Sep 12

NeuroSense Therapeutics to Present at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 10

Neurosense Therapeutics Ltd: to Effect Reverse Share Split of Co’s Ordinary Shares at Ratio of 1-for-20

THOMSON REUTERS
·
Sep 10

NeuroSense Therapeutics Effects 1-for-20 Reverse Stock Split on Sept. 14, 2026

Reuters
·
Sep 10

NeuroSense Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Sep 03

Neurosense Therapeutics Ltd. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $8

THOMSON REUTERS
·
Sep 03

NeuroSense announces redesigned development plan for PrimeC

TIPRANKS
·
Aug 31

NeuroSense Targets Faster, Lower-Cost ALS Approval Path for PrimeC Under Revamped Development Plan

Reuters
·
Aug 31

NeuroSense Plans Head-to-Head PrimeC Trial Versus Mitsubishi Tanabe’s Edaravone in ALS

Reuters
·
Aug 31

Neurosense Unveils Accelerated, Capital-Efficient Strategy to Advance Primec Toward Potential Approval in ALS

THOMSON REUTERS
·
Aug 31

NeuroSense Therapeutics Shareholders Authorized Board to Pursue Reverse Stock Split Range 1-for-4 to 1-for-40

Reuters
·
Aug 28

NeuroSense Announces Shareholder Letter Availability

Reuters
·
Aug 13

NeuroSense Targets December 2026 Canada Filing for PrimeC ALS Drug Amid Phase 3 Paragon Preparations

Reuters
·
Aug 13